Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars®. She has been working on AJMC since 2014 and has been with AJMC’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Uncertainty Metrics in AI-Assisted Mammograms Screenings; Sarah Verboom, PhD Candidate
August 25th 2025Artificial intelligence (AI) can reduce radiologist workload for breast cancer screenings and mammograms, but their review of the results is still crucial, explained Sarah Verboom of Radboud University Medical Center.
Weighing Relapse Risk Against Benefit in Advanced NSCLC Immunotherapy: Jonathan Thompson, MD, MS
August 22nd 2025In advanced non–small cell lung cancer (NSCLC), discontinuing immunotherapy after 2 years can maintain durable responses while reducing financial and toxicity burdens, with decisions guided by residual disease testing and shared decision-making, explained Jonathan Thompson, MD, MS.
AI-Assisted Mammography, Practical Applications: Sarah Verboom, PhD Candidate
August 21st 2025Artificial intelligence (AI) can enhance breast cancer screenings by prioritizing cases, allowing radiologists to focus on complex diagnoses and improve detection rates, explained Sarah Verboom of Radboud University Medical Center.
Pediatric Pharmacists Are Expanding Their Reach in Hospitals and Beyond: Marry Vuong, PharmD, BCPPS
August 16th 2025With growing roles in inpatient care and new telehealth models, pediatric pharmacists are reshaping how and where children receive specialized medication support, explained Marry Vuong, PharmD, BCPPS, of Perfecting Peds.
Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML
August 16th 2025Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.
Advancing Equitable Access to Targeted and Immuno-Oncology Therapies in SCLC: Angel Qin, MD
August 7th 2025Recent clinical trials like ADRIATIC and IMforte are shaping the future of small cell lung cancer (SCLC) treatment, explained Angel Qin, MD. She also emphasized the growing role of immunotherapy in adjuvant and maintenance therapies.